Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials

Abstract

Secukinumab significantly improves patient-reported itching, pain, and scaling in adults with moderate to severe psoriasis compared with placebo.

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

“…Moreover, the current analysis investigates the differential effects of two active treatments for moderate‐to‐severe psoriasis and the effects at different time points, which, to our knowledge, is rarely explored in SEM analyse. Leonardi and colleagues focused on the effects of pruritus severity only, whereas the present study integrated three bothersome psoriasis‐related symptoms and their interactions …”

“…Previous research has shown that patients perceive pain, itching and scaling to be the most troubling aspects of their psoriasis. 12,13 These symptoms are correlated with PASI scores 14 but the size of the correlations suggests that they capture unique patient experience not measured by the PASI itself and may affect HRQoL and work and activity impairment.…”

Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

“…In ERASURE and FIXTURE, findings from the Psoriasis Symptom Diary© indicate that improvements in PASI response rates are paralleled by significant reductions in patient-reported symptoms of itching, pain, and scaling [29]. Additionally, improvements in DLQI at Week 52 with secukinumab were sufficient to meet the definition of a clinically important difference in health-related quality of life for patients with psoriasis who are receiving biologic therapy [23].…”

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials

“…Moreover, 12 weeks of treatment with ixekizumab, which inhibits IL‐17, has shown improvement from baseline in itch severity on an 11‐point itch numeric rating scale (range, 4.9–5.4) relative to etanercept (range, 3.5–3.9; P < 0.001) or placebo (range, 0.2–0.6; P < 0.001) . Likewise, the IL‐17 inhibitor secukinumab demonstrated significant improvement in itch over placebo on an 11‐point scale after 12 weeks (change from baseline: secukinumab 150 mg, −4.90 and secukinumab 300 mg, −5.14 vs. placebo, −0.40; P < 0.0001 for both) …”